Androgenic Alopecia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: AND014 MIFTS: 41	Androgenic Alopecia Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Androgenic Alopecia

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia ¹² ¹⁵ ³³

Androgenetic Alopecia ¹² ⁷²

Alopecia Androgenetica, Male Pattern Baldness ¹²

Classifications:

MalaCards categories:
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the skin and subcutaneous tissue

Disorders of skin appendages

Androgenic alopecia

Androgenic alopecia, unspecified

External Ids:

Disease Ontology ¹² DOID:0050801

ICD10 ³³ L64 L64.9

UMLS ⁷² C0162311

Sources

Summaries for Androgenic Alopecia

Disease Ontology : ¹² An alopecia that is characterized by M-shaped hair line recession and thinning of hair at the crown of the head in males.

MalaCards based summary : Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and seborrheic dermatitis. An important gene associated with Androgenic Alopecia is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Regulation of Androgen receptor activity. The drugs Fenugreek and Fenugreek seed meal have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and ovary, and related phenotype is reproductive system.

Wikipedia : ⁷⁵ Pattern hair loss is hair loss that primarily affects the top and front of the scalp. In male-pattern... more...

Sources

Related Diseases for Androgenic Alopecia

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)

#	Related Disease	Score	Top Affiliating Genes
1	alopecia, androgenetic, 1	32.5	SRD5A2 SHBG CYP19A1 AR
2	seborrheic dermatitis	30.8	SHBG LPP
3	prostatic hypertrophy	30.6	KLK3 CYP19A1 AR
4	prostate disease	30.6	KLK3 CYP19A1 AR
5	hyperandrogenism	30.5	SHBG PRL CYP19A1
6	sexual disorder	30.4	SHBG PRL KLK3
7	polycystic ovary syndrome	30.4	SHBG PRL CYP19A1
8	impotence	30.4	SHBG PRL KLK3
9	premature ovarian failure 1	30.3	SHBG PRL CYP19A1
10	ovarian disease	30.3	SHBG PRL CYP19A1
11	hair disease	30.3	LPP EDA2R
12	prostatic hyperplasia, benign	30.0	SRD5A2 SHBG KLK3 AR
13	alopecia	30.0	SHBG KRT15 HR EDA2R AR
14	gynecomastia	29.9	SHBG PRL KLK3 CYP19A1 AR
15	prostate cancer	28.3	SRD5A2 SHBG KLK3 CYP19A1 AR
16	marie unna congenital hypotrichosis	11.5
17	hypotrichosis 1	11.4
18	hypotrichosis simplex	11.4
19	47, xxy	10.6	SHBG AR
20	postmenopausal atrophic vaginitis	10.6	SHBG AR
21	nodular prostate	10.5	KLK3 AR
22	hypoactive sexual desire disorder	10.5	SHBG CYP19A1
23	sebaceous gland disease	10.5	SHBG AR
24	pelvic varices	10.5	SHBG PRL
25	gender identity disorder	10.4	CYP19A1 AR
26	transsexualism	10.4	CYP19A1 AR
27	frontal fibrosing alopecia	10.4
28	lichen planopilaris	10.4
29	rapidly involuting congenital hemangioma	10.4
30	withdrawal disorder	10.4	KLK3 AR
31	premenstrual tension	10.4	SHBG PRL
32	male reproductive organ benign neoplasm	10.4	KLK3 CYP19A1
33	cystitis cystica	10.4	KLK3 AR
34	hermaphroditism	10.4	SRD5A2 AR
35	mammographic density	10.4	PRL CYP19A1
36	diffuse alopecia areata	10.3
37	contact dermatitis	10.3
38	oligospermia	10.3	PRL AR
39	male reproductive organ cancer	10.3	SHBG KLK3 AR
40	male reproductive system disease	10.3	SHBG KLK3 AR
41	androgen insensitivity, partial	10.3	SHBG CYP19A1 AR
42	arteries, anomalies of	10.3
43	body mass index quantitative trait locus 1	10.3
44	coronary heart disease 1	10.3
45	retinal dystrophy, iris coloboma, and comedogenic acne syndrome	10.3
46	hyperlipoproteinemia, type iii	10.3
47	infant gynecomastia	10.3
48	coronary artery anomaly	10.3
49	folliculitis	10.3
50	complete androgen insensitivity syndrome	10.3	SHBG CYP19A1 AR

Graphical network of the top 20 diseases related to Androgenic Alopecia:

Sources

Symptoms & Phenotypes for Androgenic Alopecia

MGI Mouse Phenotypes related to Androgenic Alopecia:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	reproductive system	MP:0005389	9.1	AR CYP19A1 HR LPP PRL SRD5A2

Sources

Drugs & Therapeutics for Androgenic Alopecia

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fenugreek

Phase 4

Fenugreek seed meal

Phase 4

Dutasteride

Approved, Investigational

Phase 3

164656-23-9

152945 6918296

Nitric Oxide

Approved

Phase 1, Phase 2

10102-43-9

145068

Bimatoprost

Approved, Investigational

Phase 2

155206-00-1

5311027

Acetylcholine

Approved, Investigational

Phase 2

51-84-3

187

Valproic acid

Approved, Investigational

Phase 2

99-66-1

3121

Vitamin C

Approved, Nutraceutical

Phase 1, Phase 2

50-81-7

54670067 5785

Maleic acid

Experimental, Investigational

Phase 1, Phase 2

110-17-8, 110-16-7

444972

Ammonium trichloro(dioxoethylene-O,O'-)tellurate

Phase 2

Adjuvants, Immunologic

Phase 2

Anti-Infective Agents

Phase 2

Protective Agents

Phase 1, Phase 2

Radiation-Protective Agents

Phase 2

Antiviral Agents

Phase 2

Antioxidants

Phase 1, Phase 2

Peripheral Nervous System Agents

Phase 1, Phase 2

Respiratory System Agents

Phase 1, Phase 2

Free Radical Scavengers

Phase 1, Phase 2

Endothelium-Dependent Relaxing Factors

Phase 1, Phase 2

Autonomic Agents

Phase 1, Phase 2

Anti-Asthmatic Agents

Phase 1, Phase 2

Bronchodilator Agents

Phase 1, Phase 2

HIV Protease Inhibitors

Phase 2

protease inhibitors

Phase 2

Proteasome Inhibitors

Phase 2

Androgens

Phase 2

Cholinergic Agents

Phase 2

abobotulinumtoxinA

Phase 2

Acetylcholine Release Inhibitors

Phase 2

Neurotransmitter Agents

Phase 2

Botulinum Toxins

Phase 2

Botulinum Toxins, Type A

Phase 2

Ophthalmic Solutions

Phase 2

Tranquilizing Agents

Phase 2

Central Nervous System Depressants

Phase 2

GABA Agents

Phase 2

Psychotropic Drugs

Phase 2

Anticonvulsants

Phase 2

Antimanic Agents

Phase 2

Immunologic Factors

Phase 1, Phase 2

Mitogens

Phase 1, Phase 2

Complement Factor H

Phase 1, Phase 2

Complement System Proteins

Phase 1, Phase 2

Immunosuppressive Agents

Phase 1, Phase 2

Complement Inactivating Agents

Phase 1, Phase 2

Ethanol

Approved

Phase 1

64-17-5

702

Methyltestosterone

Approved

Phase 1

58-18-4

6010

Testosterone enanthate

Approved

Phase 1

315-37-7

9416

Testosterone undecanoate

Approved, Investigational

Phase 1

5949-44-0

Interventional clinical trials:

(show top 50) (show all 116)

#	Name	Status	NCT ID	Phase	Drugs
1	Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial	Unknown status	NCT02999737	Phase 4
2	Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome	Completed	NCT02789488	Phase 4
3	the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial	Recruiting	NCT03388840	Phase 4
4	The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia	Withdrawn	NCT02483195	Phase 4	5% Minoxidil;200mg Spironolactone;5mg Finasteride
5	BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA	Unknown status	NCT01655108	Phase 3	Minoxidil;Saline
6	An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)	Completed	NCT00441116	Phase 3	Dutasteride 0.5mg oral tablets
7	A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia	Completed	NCT02014584	Phase 3	Dutasteride;Placebo
8	A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia)	Completed	NCT04019795	Phase 3
9	A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia	Completed	NCT00396175	Phase 3	MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
10	Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume	Completed	NCT00958750	Phase 3	minoxidil
11	Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia	Completed	NCT01831791	Phase 3	Dutasteride 0.5 mg
12	Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study	Completed	NCT01391156	Phase 3	3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
13	A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness	Completed	NCT03004469	Phase 3	P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
14	A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia	Completed	NCT01231607	Phase 3	1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
15	A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia)	Completed	NCT01226459	Phase 3	5% Minoxidil Topical Foam;Vehicle Topical Foam
16	A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625)	Completed	NCT01145625	Phase 3	5% Minoxidil;2% Minoxidil
17	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia	Recruiting	NCT03742518	Phase 2, Phase 3	Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
18	A Double-Blind, Randomized, Clinical Trial of the Efficacy and Safety Study to Compare Topical Herbal Solution and Minoxidil 5% in Healthy Male Subjects With Androgenetic Alopecia	Active, not recruiting	NCT03753113	Phase 3	Topical Minoxidil 5%
19	Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women	Unknown status	NCT00418249	Phase 2	AS101
20	A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men	Unknown status	NCT00471510	Phase 2	tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
21	A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia	Unknown status	NCT02528552	Phase 2
22	A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA)	Unknown status	NCT01643629	Phase 1, Phase 2
23	The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial	Unknown status	NCT01501617	Phase 1, Phase 2
24	An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA	Unknown status	NCT01650272	Phase 1, Phase 2	5% MInoxidil milky lotion;5% Minoxidil solution
25	A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant	Unknown status	NCT01644422	Phase 1, Phase 2
26	Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia	Unknown status	NCT01347957	Phase 1, Phase 2
27	Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial	Completed	NCT02150187	Phase 2
28	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)	Completed	NCT02275351	Phase 2	SM04554;Vehicle
29	A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia	Completed	NCT02280603	Phase 1, Phase 2	DA-4001C;5% minoxidil
30	A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)	Completed	NCT02279823	Phase 2	CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
31	A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing	Completed	NCT02503137	Phase 2	Topical SM04554 solution;Topical Vehicle solution
32	A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men	Completed	NCT00418730	Phase 2	tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
33	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males	Completed	NCT02781311	Phase 2	Setipiprant;Placebo;Finasteride
34	A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia	Completed	NCT00965640	Phase 2	Botulinum Toxin - A injections
35	A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)	Completed	NCT01904721	Phase 2	Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
36	A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects	Completed	NCT01451190	Phase 2
37	A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects.	Completed	NCT01451177	Phase 2
38	A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects	Completed	NCT01451151	Phase 2
39	A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects	Completed	NCT01451138	Phase 2
40	A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil	Completed	NCT01451125	Phase 2
41	A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects	Completed	NCT01451112	Phase 2
42	A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss	Completed	NCT01451099	Phase 2
43	A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss	Completed	NCT01451073	Phase 2
44	A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss	Completed	NCT01451047	Phase 2
45	A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss	Completed	NCT01451021	Phase 2
46	A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia	Completed	NCT01669746	Phase 2
47	Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks	Completed	NCT01319370	Phase 2	Minoxidil;vehicle of 5% Minoxidil topical foam
48	Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia.	Completed	NCT01286649	Phase 1, Phase 2
49	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Completed	NCT01325337	Phase 2	bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
50	Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia	Completed	NCT02865421	Phase 2	stem cells;platelet rich plasma

Search NIH Clinical Center for Androgenic Alopecia

Sources

Genetic Tests for Androgenic Alopecia

Sources

Anatomical Context for Androgenic Alopecia

MalaCards organs/tissues related to Androgenic Alopecia:

⁴¹

Skin, Prostate, Ovary, Testes, Bone, Endothelial, Brain

Sources

Publications for Androgenic Alopecia

Articles related to Androgenic Alopecia:

(show top 50) (show all 1646)

#	Title	Authors	PMID	Year
1	Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. ³⁸	Panchaprateep R...Kalpongnukul N	30843235	2019
2	Shedding light on the FDA's 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia. ³⁸	Wang S...Scott J	30252550	2019
3	Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. ³⁸	Ghonemy S...Alarawi A	31403367	2019
4	Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. ³⁸	Suchonwanit P...Khunkhet S	30569416	2019
5	The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards the future. ³⁸	Wipf A...Farah RS	30300013	2019
6	Erosive pustular dermatosis of the scalp: A neutrophilic folliculitis within the spectrum of neutrophilic dermatoses: A clinicopathologic study of 30 cases. ³⁸	Tomasini C...Michelerio A	30617027	2019
7	Pediatric Androgenetic Alopecia: a Review. ³⁸	Griggs J...Tosti A	31415838	2019
8	Efficacy of platelet-rich plasma in androgenetic alopecia patients. ³⁸	Butt G...Choudhery MS	30393988	2019
9	An overview of herbal alternatives in androgenetic alopecia. ³⁸	Dhariwala MY...Ravikumar P	30980598	2019
10	Androgenetic alopecia and microneedling: Every needling is not microneedling. ³⁸	Jha AK...Vinay K	30905794	2019
11	Investigation on Microecology of Hair Root Fungi in Androgenetic Alopecia Patients. ³⁸	Huang J...Dai Y	31240449	2019
12	Do Kimchi and Cheonggukjang Probiotics as a Functional Food Improve Androgenetic Alopecia? A Clinical Pilot Study. ³⁸	Park DW...Seo JT	31385480	2019
13	Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. ³⁸	Jimenez-Cauhe J...Vano-Galvan S	31054970	2019
14	Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and anti-androgens. ³⁸	Katzer T...Silva CB	31400254	2019
15	Phospholipid-polymer hybrid nanoparticles mediated transfollicular delivery of Quercetin: prospective implement for the treatment of androgenic alopecia. ³⁸	Das L...Pandey RS	31382790	2019
16	Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. ³⁸	Liu KH...Chin SY	30706177	2019
17	Expression of anti-aging type-XVII collagen (COL17A1/BP180) in hair follicle-associated pluripotent (HAP) stem cells during differentiation. ³⁸	Shirai K...Amoh Y	31383286	2019
18	Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. ³⁸	Melcangi RC...Simoni M	31272082	2019
19	A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. ³⁸	Zhang L...Li X	30566260	2019
20	Finasteride Enhances Stem Cell Signals of Human Dermal Papilla Cells. ³⁸	Rattanachitthawat N...Chanvorachote P	31280211	2019
21	Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. ³⁸	Carmina E...Olsen E	30785992	2019
22	Long-term treatment with finasteride induces apoptosis and pathological changes in female mice. ³⁸	Alkahtane AA...Alkahtani S	30943778	2019
23	Histopathology of aging of the hair follicle. ³⁸	Fernandez-Flores A...Cassarino DS	30932205	2019
24	Biofibre® artificial hair implant: Retrospective study on 1,518 patients with alopecia and present role in hair surgery. ³⁸	Satolli F...Tchernev G	31168904	2019
25	Letter in response to "The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia". ³⁸	Malayanur D...Mysore V	30880717	2019
26	Generation of an integration-free human induced pluripotent stem cell line MUSIi010-A from occipital scalp fibroblasts of a male patient with androgenetic alopecia. ³⁸	Tantarungsee N...Thuangtong R	31228683	2019
27	Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. ³⁸	Haber RS...Foley KA	30835851	2019
28	Photographic assessment improves adherence to recommended follow-up in patients with androgenetic alopecia and alopecia areata: A retrospective cohort study. ³⁸	Lee S...Lee WS	31062723	2019
29	Reproductive endocrinologists are the gatekeepers for male infertility care in North America: results of a North American survey on the referral patterns and characteristics of men presenting to male infertility specialists for infertility investigations. ³⁸	Samplaski MK...Jarvi KA	31351700	2019
30	Cholesterol homeostasis: Links to hair follicle biology and hair disorders. ³⁸	Palmer MA...Haslam IS	31260136	2019
31	Adipose Infiltration of the Dermis, Involving the Arrector Pili Muscle, and Dermal Displacement of Eccrine Sweat Coils: New Histologic Observations in Frontal Fibrosing Alopecia. ³⁸	Miteva M...Sabiq S	30624243	2019
32	Autologous Cellular Method Using Micrografts of Human Adipose Tissue Derived Follicle Stem Cells in Androgenic Alopecia. ³⁸	Gentile P	31337037	2019
33	Platelet-Rich Plasma and Its Utilities in Alopecia: A Systematic Review. ³⁸	Hesseler MJ...Shyam N	31211715	2019
34	Harvested vs estimated follicular units in hair transplantation. ³⁸	Huang YL...Cheng CY	30084223	2019
35	Efficacy of Platelet-rich Plasma for Treating Androgenic Alopecia of Varying Grades. ³⁸	Qu Q...Hu Z	31228018	2019
36	Preliminary results of the use of scalp microneedling in different types of alopecia. ³⁸	Starace M...Piraccini BM	31254437	2019
37	Fibrosing Alopecia in a Pattern Distribution (FAPD) in 16 African-Descent and Hispanic Female Patients: A Challenging Diagnosis. ³⁸	Teixeira MS...Vilar EAG	31367598	2019
38	The diagnosis of androgenetic alopecia in children: Considerations of pathophysiological plausibility. ³⁸	Rossi A...Carlesimo M	31168786	2019
39	Progressive expression of PPARGC1α is associated with hair miniaturization in androgenetic alopecia. ³⁸	Ho BS...Bigliardi PL	31217429	2019
40	Development of finasteride polymer microspheres for systemic application in androgenic alopecia. ³⁸	Kim JH...Lee HS	30942390	2019
41	Relationship between androgenic alopecia and white matter hyperintensities in apparently healthy subjects. ³⁸	Ata Korkmaz HA	31250269	2019
42	Platelet-Rich Plasma for Treating Androgenic Alopecia: A Systematic Review. ³⁸	Mao G...Fan W	31187167	2019
43	Herbal Medicines For Treatment of Androgenic Alopecia. ³⁸	Asnaashari S...Javadzadeh Y	31221945	2019
44	Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. ³⁸	Sharma A...McCoy J	30974011	2019
45	Correlation of Trichoscopic Findings in Androgenetic Alopecia and the Disease Severity. ³⁸	Ummiti A...Kumar CS	31360040	2019
46	Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. ³⁸	Melo DF...Tortelly VD	31066492	2019
47	Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. ³⁸	Shin YS...Park JK	30209896	2019
48	Prostaglandins in androgenetic alopecia in 12 men and four female. ³⁸	Villarreal-Villarreal CD...Ocampo-Candiani J	30730082	2019
49	Hair distribution width - a novel trichoscopy parameter for hair miniaturization in androgenetic alopecia. ³⁸	Majd A...Lee TK	31066933	2019
50	A semiquantitative grading scale for frontal and vertex of androgenetic alopecia. ³⁸	Nie J...Hou W	30592306	2019

Sources

Genes for Androgenic Alopecia

Genes related to Androgenic Alopecia (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SHBG	Sex Hormone Binding Globulin	Protein Coding	23.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	AR	Androgen Receptor	Protein Coding	23.34	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	EFNA3	Ephrin A3	Protein Coding	21.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	KLK3	Kallikrein Related Peptidase 3	Protein Coding	20.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	PRL	Prolactin	Protein Coding	20.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	EDA2R	Ectodysplasin A2 Receptor	Protein Coding	17.44	DISEASES inferred ¹⁵
7	SRD5A2	Steroid 5 Alpha-Reductase 2	Protein Coding	16.74	DISEASES inferred ¹⁵
8	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	16.62	GeneCards inferred via : Publications (show sections)
9	HR	HR Lysine Demethylase And Nuclear Receptor Corepressor	Protein Coding	16.62	GeneCards inferred via : Publications (show sections)
10	LPP	LIM Domain Containing Preferred Translocation Partner In Lipoma	Protein Coding	15.84	DISEASES inferred ¹⁵
11	KRT15	Keratin 15	Protein Coding	15.46	DISEASES inferred ¹⁵
12	GGN	Gametogenetin	Protein Coding	15.42	DISEASES inferred ¹⁵

Sources

Variations for Androgenic Alopecia

Sources

Expression for Androgenic Alopecia

Search GEO for disease gene expression data for Androgenic Alopecia.

Sources

Pathways for Androgenic Alopecia

Pathways related to Androgenic Alopecia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	11.3	SRD5A2 KLK3 AR
2	Regulation of Androgen receptor activity ¹	11.02	KLK3 AR
3	FOXA1 transcription factor network ¹ Show member pathways FOXA transcription factor networks ¹	10.92	KLK3 AR
4	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	10.81	CYP19A1 AR
5	Nongenotropic Androgen signaling ¹	9.88	SHBG AR

Sources

GO Terms for Androgenic Alopecia

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cell-cell signaling	GO:0007267	9.63	SRD5A2 EFNA3 AR
2	negative regulation of angiogenesis	GO:0016525	9.5	PRL KLK3 EFNA3
3	mammary gland development	GO:0030879	9.43	PRL CYP19A1
4	sex differentiation	GO:0007548	9.4	SRD5A2 AR
5	androgen metabolic process	GO:0008209	9.37	SRD5A2 CYP19A1
6	regulation of systemic arterial blood pressure	GO:0003073	9.26	KLK3 AR
7	prostate gland growth	GO:0060736	9.16	CYP19A1 AR
8	testosterone biosynthetic process	GO:0061370	8.96	SRD5A2 CYP19A1
9	female genitalia development	GO:0030540	8.32	CYP19A1

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	steroid binding	GO:0005496	8.96	SHBG AR
2	androgen binding	GO:0005497	8.62	SHBG AR

Sources

Sources for Androgenic Alopecia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia